Bruce M Halpryn
Vorstandsvorsitzender bei Eikonoklastes Therapeutics, Inc.
Profil
Bruce M Halpryn is the founder of Myonexus Therapeutics, Inc. which was founded in 2017.
He held the title of Chief Operating Officer, Secretary & Director at Myonexus Therapeutics, Inc. from 2017 to 2024.
Dr. Halpryn is currently the Chairman & Chief Executive Officer at Eikonoklastes Therapeutics, Inc.
Aktive Positionen von Bruce M Halpryn
| Unternehmen | Position | Beginn |
|---|---|---|
Eikonoklastes Therapeutics, Inc.
 Eikonoklastes Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Eikonoklastes Therapeutics, Inc. provides pharmaceutical services. It develops a state of the art immune conjugate technology targeting tissue factor for the treatment of solid tumors and other pathologic conditions. The company was founded by Zhiwei Hu and is headquartered in Cincinnati, OH. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Bruce M Halpryn
| Unternehmen | Position | Ende |
|---|---|---|
Myonexus Therapeutics, Inc.
 Myonexus Therapeutics, Inc. BiotechnologyHealth Technology Myonexus Therapeutics, Inc. operates as a clinical stage company. It engages in the research and development of limb-girdle muscular dystrophy gene treatments. The company was founded by Michael Triplett and Bruce Halpryn in February 2017 and is headquartered in New Albany, OH. | Gründer | 01.04.2024 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Myonexus Therapeutics, Inc.
Myonexus Therapeutics, Inc. BiotechnologyHealth Technology Myonexus Therapeutics, Inc. operates as a clinical stage company. It engages in the research and development of limb-girdle muscular dystrophy gene treatments. The company was founded by Michael Triplett and Bruce Halpryn in February 2017 and is headquartered in New Albany, OH. | Health Technology |
Eikonoklastes Therapeutics, Inc.
Eikonoklastes Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Eikonoklastes Therapeutics, Inc. provides pharmaceutical services. It develops a state of the art immune conjugate technology targeting tissue factor for the treatment of solid tumors and other pathologic conditions. The company was founded by Zhiwei Hu and is headquartered in Cincinnati, OH. | Health Technology |